)
Visual
test
MetaVia
MetaVia (MTVA) investor relations material
MetaVia Registration Filing summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Registration Filing summary12 Jan, 2026
Offering details and pricing
Up to 919,681 Class A Units (each: 1 share, 1.5 Series C, 1.5 Series D warrants) or 919,681 Class B Units (each: 1 pre-funded warrant, 1.5 Series C, 1.5 Series D warrants) are offered at an assumed price of $8.155 per unit, based on the last Nasdaq close.
Series C warrants are exercisable for five years; Series D for two years and callable under certain conditions; pre-funded warrants have a $0.001 exercise price and no expiration.
The underwriters have a 45-day option to purchase up to 137,952 additional shares and/or 413,856 additional warrants.
Estimated net proceeds are $6.0 million (or $7.0 million if the over-allotment is exercised), assuming no Class B Units are sold and no warrants are exercised.
The offering is underwritten by Ladenburg Thalmann & Co. Inc.
Company overview and business model
Clinical-stage biotechnology company focused on novel pharmaceuticals for cardiometabolic diseases, with lead programs in MASH and obesity.
Lead assets: Vanoglipel (DA-1241), a GPR119 agonist for MASH and T2DM, and DA-1726, a GLP1R/GCGR dual agonist for obesity.
Vanoglipel has completed Phase 2a with positive topline results; DA-1726 is in Phase 1 with positive data and further dose escalation planned.
Four legacy programs are not being advanced and are considered for out-licensing or divestiture.
Financial performance and metrics
As of December 31, 2025 (preliminary, unaudited): cash and equivalents of ~$10.3 million, no debt.
Net loss of $11.0 million for the nine months ended September 30, 2025; accumulated deficit of $146.9 million.
R&D expenses decreased 62.5% year-over-year for the nine months ended September 30, 2025, reflecting lower clinical activity.
Cash runway expected into Q3 2026 with proceeds from this offering.
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Latest summaries
- TimeTickerHeadlineOpen
- SANSERA
Q1 FY25 delivered double-digit growth, margin expansion, and a record order book despite global headwinds. - JKHY
Record revenue, margin, and EPS growth drive raised guidance and strong segment momentum. - IEX
Record HST-driven growth and margin gains support 2026 outlook amid industrial headwinds. - KREF
Net loss for 2025, but strong liquidity, portfolio repositioning, and active capital management. - ODFL
Q4 revenue and earnings declined, but yield, service, and capital returns remained strong. - ORN
Acquisition expands marine construction scale and reach, supporting long-term profitable growth. - THG
Record earnings, improved underwriting, and strong capital actions drive robust 2025 results. - BAM
Record earnings, 15% dividend increase, and major AI initiatives drive robust growth. - LLY
Q4 2025 revenue up 43% to $19.3B; 2026 guidance: $80–$83B revenue, $33.50–$35 EPS. - CDW
2025 sales and profits rose, with strong cash returns and 2026 growth set to outpace the market.
Next MetaVia earnings date
Q4 202526 Mar, 2026
MetaVia
Next MetaVia earnings date
Q4 202526 Mar, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
MetaVia Inc is a U.S.-based biotechnology company focused on developing treatments for metabolic and rare genetic diseases. The company is engaged in the research and clinical development of novel therapeutics targeting underlying disease mechanisms, with a goal of addressing unmet medical needs. MetaVia utilizes proprietary technology platforms and collaborates with research institutions to advance its pipeline. The company is headquartered in South San Francisco, California, and its shares are listed on the NASDAQ.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage